Explore the full hierarchy of this title across chapters, subchapters, and parts.
Select a part from the tree to begin
Browse chapters and parts on the left to load sections
United States • Title 21 CFR • Part 343
This part of the CFR outlines the conditions under which over-the-counter (OTC) internal analgesic, antipyretic, and antirheumatic drug products are generally recognized as safe and effective (GRASE) and not misbranded. It specifies requirements for scope, definitions, active ingredients (aspirin, buffered aspirin), permitted combinations, and professional labeling.
(a) An over-the-counter analgesic-antipyretic drug product in a form suitable for oral administration is generally recognized as safe and effective and is not misbranded if it meets each of the conditions in this part in addition to each of the general conditions established in § 330.1 of this chapter. (b) References in this part to regulatory sections of the Code of Federal Regulations are to chapter I of title 21 unless otherwise noted.
(a) Aspirin. (b) Buffered aspirin. Aspirin identified in paragraph (a) of this section may be buffered with any antacid ingredient(s) identified in § 331.11 of this chapter provided that the finished product contains at least 1.9 milliequivalents of acid-neutralizing capacity per 325 milligrams of aspirin as measured by the procedure provided in the United States Pharmacopeia 23/National Formulary 18.
(a) Aspirin. (b) Buffered aspirin. Aspirin identified in paragraph (a) of this section may be buffered with any antacid ingredient(s) identified in § 331.11 of this chapter provided that the finished product contains at least 1.9 milliequivalents of acid-neutralizing capacity per 325 milligrams of aspirin as measured by the procedure provided in the United States Pharmacopeia 23/National Formulary 18.
Combinations containing aspirin must meet the standards of an acceptable dissolution test, as set forth in § 343.90. The following combinations are permitted: Aspirin identified in §§ 343.12 and 343.13 may be combined with any antacid ingredient identified in § 331.11 of this chapter or any combination of antacids permitted in accordance with § 331.10(a) of this chapter provided that the finished product meets the requirements of § 331.10 of this chapter and is marketed in a form intended for ingestion as a solution.
As used in this part: Analgesicantipyretic drug.— An agent used to alleviate pain and to reduce fever. Cardiovascular drug. An agent used to prevent ischemic events. Rheumatologic drug. An agent used for the treatment of rheumatologic disorders.
The labeling of an over-the-counter drug product written for health professionals (but not for the general public) shall consist of the following: For products containing aspirin identified in §§ 343.12 and 343.13 or permitted combinations identified in § 343.22.(a) (These products must meet United States Pharmacopeia (USP) standards for dissolution or drug release in § 343.90.) (1) The labeling contains the following prescribing information under the heading “Comprehensive Prescribing Information” and the subheadings “Description,” “Clinical Pharmacology,” “Clinical Studies,” “Animal Toxicology,” “Indications and Usage,” “Contraindications,” “Warnings,” “Precautions,” “Adverse Reactions,” “Drug Abuse and Dependence,” “Overdosage,” “Dosage and Administration,” and “How Supplied” in the exact language and the exact order provided as follows: REV: October 23, 1998. (2) In addition to, and immediately preceding, the labeling required under paragraph (a)(1) of this section, the professional labeling may contain the following highlights of prescribing information in the exact language and exact format provided, but only when accompanied by the comprehensive prescribing information…
(a) [Reserved] Aspirin capsules.(b) Aspirin capsules must meet the dissolution standard for aspirin capsules as contained in the United States Pharmacopeia (USP) 23 at page 132. Aspirin delayed-release capsules and aspirin delayed-release tablets.(c) Aspirin delayed-release capsules and aspirin delayed-release tablets must meet the drug release standard for aspirin delayed-release capsules and aspirin delayed-release tablets as contained in USP 23 at pages 133 and 136 respectively. Aspirin tablets.(d) Aspirin tablets must meet the dissolution standard for aspirin tablets as contained in USP 23 at page 134. Aspirin, alumina, and magnesia tablets.(e) Aspirin in combination with alumina and magnesia in a tablet dosage form must meet the dissolution standard for aspirin, alumina, and magnesia tablets as contained in USP 23 at page 138. Aspirin, alumina, and magnesium oxide tablets.(f) Aspirin in combination with alumina, and magnesium oxide in a tablet dosage form must meet the dissolution standard for aspirin, alumina, and magnesium tablets as contained in USP 23 at page 139. Aspirin effervescent tablets for oral solution.(g) Aspirin effervescent tablets for oral solution must…
This document sits within United States CFR and is most useful when linked to operational submission, quality, and inspection workflows.